New therapies for type 2 diabetes based on glucagon-like peptide 1.
Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.
Salehi
Marzieh
M
Division of Endocrinology and Metabolism, University of Cincinnati Medical Center, Cincinnati, OH 45267-0547, USA. salehim@email.uc.edu
D'Alessio
David A
DA
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1